ALK and anaplastic large cell lymphoma: There are currently four ongoing clinical trials of crizotinib (NCT00939770, NCT01606878, NCT01524926, NCT00585195) and one of a dual ALK/EGFR inhibitor AP26113 (NCT01449461) in ALCL patients.